Zhou L, Yang S, Li Y, Xue C, Wan R
Front Immunol. 2024; 15:1448728.
PMID: 39559363
PMC: 11570264.
DOI: 10.3389/fimmu.2024.1448728.
Izumi K, Iyoda T, Yokota A, Kanno M, Hoshi M, Tokuda E
Support Care Cancer. 2024; 32(11):735.
PMID: 39422777
DOI: 10.1007/s00520-024-08928-y.
Mima Y, Ohtsuka T, Ebato I, Nakata Y, Tsujita A, Nakazato Y
Biomedicines. 2024; 12(8).
PMID: 39200350
PMC: 11352049.
DOI: 10.3390/biomedicines12081886.
Yan S, Fan J
World J Gastroenterol. 2024; 30(21):2734-2739.
PMID: 38899328
PMC: 11185298.
DOI: 10.3748/wjg.v30.i21.2734.
Angel Garcia J, Alcaraz D, Holgado E, Counago F
World J Clin Oncol. 2024; 15(5):576-579.
PMID: 38835848
PMC: 11145962.
DOI: 10.5306/wjco.v15.i5.576.
Endocrine system-related adverse events associated with PD-1/PD-L1 inhibitors: data mining from the FDA adverse event reporting system.
Shi H, He Y, Dan S, Yang L, Wang J, Chen L
Front Med (Lausanne). 2024; 11:1366691.
PMID: 38711784
PMC: 11073539.
DOI: 10.3389/fmed.2024.1366691.
Challenges in autoimmune polyendocrine syndrome type 2 with the full triad induced by anti-programmed cell death 1: a case report and review of the literature.
Pan Q, Li P
Front Immunol. 2024; 15:1366335.
PMID: 38707904
PMC: 11067522.
DOI: 10.3389/fimmu.2024.1366335.
A Case in Which HLA-DR4 is Involved in the Development of Complex Immune-Related Endocrinological Adverse Events following Combination Therapy with Nivolumab and Ipilimumab.
Kidawara Y, Kadoya M, Kakutani-Hatayama M, Koyama H
Case Rep Endocrinol. 2024; 2024:4662803.
PMID: 38559614
PMC: 10980546.
DOI: 10.1155/2024/4662803.
Reaching the Diagnosis of Checkpoint Inhibitor-Induced Diabetes Mellitus in Different Clinical Scenarios: A Real-World Application of Updated Diagnostic Criteria.
Angelousi A, Ziogas D, Siampanopoulou V, Mytareli C, Anastasopoulou A, Lyrarakis G
Diseases. 2024; 12(2).
PMID: 38391787
PMC: 10887699.
DOI: 10.3390/diseases12020040.
Extraislet expression of islet antigen boosts T cell exhaustion to partially prevent autoimmune diabetes.
Selck C, Jhala G, De George D, Kwong C, Christensen M, Pappas E
Proc Natl Acad Sci U S A. 2024; 121(6):e2315419121.
PMID: 38285952
PMC: 10861925.
DOI: 10.1073/pnas.2315419121.
Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review.
Fujiwara M, Shimizu M, Okano T, Maejima Y, Shimomura K
Front Public Health. 2023; 11:1264056.
PMID: 38106883
PMC: 10725247.
DOI: 10.3389/fpubh.2023.1264056.
Anti-GAD antibody-positive fulminant type 1 diabetes developed following SARS-CoV-2 vaccination.
Izumi T, Takahashi H, Takahashi H
Diabetol Int. 2023; 14(4):422-426.
PMID: 37781472
PMC: 10533421.
DOI: 10.1007/s13340-023-00648-8.
T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy.
Stephen B, Hajjar J, Sarda S, Duose D, Conroy J, Morrison C
J Immunother Cancer. 2023; 11(8).
PMID: 37604642
PMC: 10445351.
DOI: 10.1136/jitc-2023-007236.
Gastric neuroendocrine carcinoma presenting complete durable response by nivolumab treatment for multiple metastases and radiotherapy to oligoprogressive metastasis.
Seyama Y, Yamada T, Suzuki H, Fukuda S, Tsuji M, Niisato Y
Int Cancer Conf J. 2023; 12(4):268-273.
PMID: 37577341
PMC: 10421835.
DOI: 10.1007/s13691-023-00611-z.
Clinical and immunological characteristics of PD-1 associated fulminant type 1 diabetes mellitus.
Qiu J, Luo S, Yin W, Li X, Zhou Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023; 48(1):49-58.
PMID: 36935177
PMC: 10930557.
DOI: 10.11817/j.issn.1672-7347.2023.220290.
Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors.
Caulfield J, Aizenbud L, Perdigoto A, Meffre E, Jilaveanu L, Michalek D
J Immunother Cancer. 2023; 11(3).
PMID: 36898736
PMC: 10008335.
DOI: 10.1136/jitc-2022-006570.
Changes and correlations of T-cell coinhibitory molecule programmed death-1 and interferon-γ in pediatric immune thrombocytopenia.
El-Gendy F, Shehata A, El-Kawy E, Ahmed El-Hawy M
Clin Exp Pediatr. 2023; 66(3):127-133.
PMID: 36823790
PMC: 9989722.
DOI: 10.3345/cep.2022.00920.
Risk of diabetes mellitus among users of immune checkpoint inhibitors: A population-based cohort study.
Chan J, Lee S, Kong D, Lakhani I, Ng K, Dee E
Cancer Med. 2023; 12(7):8144-8153.
PMID: 36647331
PMC: 10134274.
DOI: 10.1002/cam4.5616.
Characterization of immune checkpoint inhibitor-associated fulminant type 1 diabetes associated with autoantibody status and ethnic origin.
Qiu J, Luo S, Yin W, Guo K, Xiang Y, Li X
Front Immunol. 2022; 13:968798.
PMID: 36451831
PMC: 9702060.
DOI: 10.3389/fimmu.2022.968798.
Late-onset acute type 1 diabetes mellitus 7 months after discontinuation of pembrolizumab against lung cancer.
Ichihara S, Kunishige M, Kadota N, Okano Y, Machida H, Hatakeyama N
Thorac Cancer. 2022; 14(1):81-84.
PMID: 36411591
PMC: 9807438.
DOI: 10.1111/1759-7714.14736.
